Intelligence · Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring ≤24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.
-
US 10188751
Papillomavirus pseudoviruses for detection and therapy of tumors
granted -
US 10188714
Yeast-MUC1 immunotherapeutic compositions and uses thereof
granted -
US 10182994
Nanoparticulate complex of nicotine and cerium oxide and use thereof
granted -
US 10183080
Use of single dendritic wedge cell penetrating peptides to facilitate cellular delivery of nanoparticles and nanoparticles carrying cargos
granted -
US 10184004
CD47 targeted therapies for the treatment of infectious disease
granted -
US 10174098
Anti-human papillomavirus 16 E7 T cell receptors
granted -
US 10172951
Dendrimer based nanodevices for therapeutic and imaging purposes
granted -
US 10173998
Antifungal compound process
granted -
US 10172933
Mosaic vaccines for serotype a foot-and-mouth disease virus
granted -
US 10172911
Methods of modulating erythropoiesis with arginine vasopressin receptor 1B molecules
granted -
US 10166277
Vault immunotherapy
granted -
US 10166244
Targeting NCCA-ATP channel for organ protection following ischemic episode
granted -
US 10166299
AAV mediated aquaporin gene transfer to treat Sjogren's syndrome
granted -
US 10166285
Recombinant virus with diminished latency and methods of using same
granted -
US 10166255
Intracellular genomic transplant and methods of therapy
granted -
US 10167247
Solid forms of treprostinil
granted -
US 10159681
Method for on-demand contraception
granted -
US 10160957
Development of dengue virus vaccine components
granted -
US 10160802
Anti-malarial compositions
granted -
US 10160795
Neutralizing antibodies to Ebola virus glycoprotein and their use
granted -
US 10155043
Compositions containing a bitter tastant and at least one sophorolipid, and methods of reducing bitter taste attributed to a bitter tastant in an edible composition
granted -
US 10154982
Ketone bodies and ketone body esters as blood lipid lowering agents
granted -
US 10154965
Osmotic drug delivery system
granted -
US 10149470
Methods and compositions for vein harvest and autografting
granted -
US 10143724
Anti-SSX-2 T cell receptors and related materials and methods of use
granted -
US 10143709
Use of ASC and ASC-CM to treat ARDS, SARS, and MERS
granted -
US 10143721
Combination product for the prevention of sexually transmitted infections
granted -
US 10138277
Virus-like particles and methods of use
granted -
US 10137136
Methods for inhibiting muscle atrophy
granted -
US 10137188
Cell lines for virus production and methods of use
granted -
US 10138271
Native and agonist CTL epitopes of the MUC1 tumor antigen
granted -
US 10137190
Nucleic acid molecules encoding ferritin-hemagglutinin fusion proteins
granted -
US 10137212
Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications
granted -
US 10130671
Chardonnay grape seed products for nonalcoholic fatty liver disease
granted -
US 10130593
Methods of regulating cannabinoid receptor activity-related disorders and diseases
granted -
US 10131659
Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof
granted -
US 10130700
Polyvalent influenza virus-like particles (VLPS) and use as vaccines
granted -
US 10130594
Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
granted -
US 10125112
Modulators of the relaxin receptor 1
granted -
US 10124043
Mutant OPAA enzymes with increased catalytic efficiency on organophosphorus compound EA1356
granted -
US 10125172
Conformationally stabilized RSV pre-fusion F proteins
granted -
US 10119172
Methods and reagents for detecting ebola virus
granted -
US 10117942
Photoactivatable lipid-based nanoparticles as vehicles for dual agent delivery
granted -
US 10117947
Virus-like particle conjugates for diagnosis and treatment of tumors
granted -
US 10118948
Antimicrobial peptides, pharmaceutical compositions, and methods of use thereof
granted -
US 10114019
Bacterial challenge model in cattle using a trans- and intra-dermal route to infect peripheral lymph nodes
granted -
US 10113183
Adeno-associated virus vectors for treatment of glycogen storage disease
granted -
US 10111927
Pseudomonas exotoxin A with less immunogenic B cell epitopes
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory